| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
Background: We previously reported that the continuous geriatric assessments (GAs) were feasible in elderly pts with GI cancers. It is suggested that the changes in GAs might be useful. Methods: We conducted a prospective study in patients (pts) with pancreatic cancer. The primary end point was overall survival, and the secondary end points were progression free survival, toxicities, and quality of life. Eligible pts were aged 70 years or older; treating with GEM or GEM-nabPTX; and a Performance Status of 0-2. We performed the GAs before initial treatment and every two months after induction. The GAs were; Cancer-Specific Geriatric Assessment (CSGA), MMSE, Frontal Assessment Battery (FAB) and VES-13. Results: 52 pts were enrolled at Kyorin university hospital between July, 2013, and August, 2015. Conclusion: In elderly pts with pancreatic cancer, the continuous GAs were feasible. As this study is on-going, we will explore the relationship between the GAs and clinical outcomes.
|
